RNAZ (TransCode Therapeutics) Interest Expense : $-0.04 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is TransCode Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. TransCode Therapeutics's interest expense for the three months ended in Sep. 2024 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. TransCode Therapeutics's Operating Income for the three months ended in Sep. 2024 was $ -2.15 Mil. TransCode Therapeutics's Interest Expense for the three months ended in Sep. 2024 was $ -0.01 Mil. TransCode Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TransCode Therapeutics Interest Expense Historical Data

The historical data trend for TransCode Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransCode Therapeutics Interest Expense Chart

TransCode Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.16

-0.40

-0.10

-0.03

-0.06

TransCode Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-0.02	-0.02	-0.01	-	-0.01

TransCode Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

TransCode Therapeutics (NAS:RNAZ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

TransCode Therapeutics's Interest Expense for the three months ended in Sep. 2024 was $-0.01 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-2.15 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $0.00 Mil.

TransCode Therapeutics's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

TransCode Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

TransCode Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Liberty Square, Suite 2382, Boston, MA, USA, 02109

Website

https://www.transcodetherapeutics.com

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Executives

Robert Michael Dudley	director, 10 percent owner, officer: Chief Executive Officer	C/O TRANSCODE THERAPEUTICS, 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Thomas A Fitzgerald	director, officer: VP, Chief Financial Officer	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Philippe Calais	director	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Anna Moore	10 percent owner	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Zdravka Medarova	10 percent owner	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Erik Manting	director	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109